Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News on Cancer

NHS hospital performance in England: Latest numbers and trends

Some 180,329 people had been waiting more than a year to start routine hospital treatment at the end of September.

Evening Standard

EnGene Encouraged By Promising Response Rates In Bladder Cancer Trial

enGene Holdings Inc. (NASDAQ:ENGN) stock is edging higher on Tuesday, with a session volume of 18.62 million compared to an average volume of 266.85 thousand, as per data from Benzinga Pro.

Benzinga

South Carolina pays estate of patient who died following days in agony after surgeons left a blade inside him

Jeffrey Alan Fulcher, a 58-year-old husband and father of three, died after a minimally invasive surgery

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression

The U.S. Food and Drug Administration (FDA) approved on Thursday Johnson Johnson’s (NYSE:JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for a type of blood cancer.

Benzinga

Blood Pressure Medication Recalled Because Of Cancer Risk: What Is Prazosin Hydrochloride

Teva Pharmaceuticals orders a nationwide recall of their Prazosin Hydrochloride capsules.

International Business Times UK

Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement

Tango Therapeutics Inc. (NASDAQ:TNGX) revealed data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with MTAP-deleted cancers.

Benzinga

‘Tongue cancer made it hard to speak and eat - but new smart jab treatment changed my life’

Head and neck cancer is the sixth most common cancer worldwide, with around 12,800 new cases each year in the UK alone

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca/Daiichi Sankyo Partnered Breast Cancer Drug Shows Survival Benefit Over Chemotherapy

AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo on Monday released high-level results from the TROPION-Breast02 Phase 3 trial.

Benzinga

Sunbeds should be banned in the UK to cut skin cancer rates, experts say

Exposure to ultraviolet radiation from sunbeds was confirmed to be carcinogenic to humans in 2009 by the International Agency for Research on Cancer.

The Independent UK

Sick Of It All singer Lou Koller says his oesophageal cancer has returned

The hardcore vocalist was first diagnosed with the disease in summer 2024 and said he was cancer-free in May

Metal Hammer

Sanofi Expands Insulin Savings Program To Cover All US Patients

The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA’s (NASDAQ: SNY) Genzyme Corporation.

Benzinga

Three in four English hospitals failing to hit two cancer targets in league tables

Exclusive: Cancer experts declare ‘national emergency’ as hospitals miss targets on diagnosis and starting treatment

The Guardian - UK

Warning after cancer patients died following delays in getting life-saving emergency drugs

More than a dozen cancer patients have either died or become seriously ill after not getting rasburicase

The Independent UK

EXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven Cancers

Hoth Therapeutics Inc. (NASDAQ:HOTH) on Tuesday announced combined findings from multiple preclinical programs evaluating its precision antisense candidate HT-KIT.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

HCW Biologics' Shares Surge After Unveiling Next-Gen Cancer Immunotherapy Platform

HCW Biologics Inc. (NASDAQ:HCWB) stock is trading higher on Monday, with a session volume of 10.85 million compared to the average volume of 132.51K as per data from Benzinga Pro.

The Independent UK

Thousands referred for liver cancer checks after on-the-spot scan

Some 112,831 people have had a mobile scan of their liver under the NHS scheme

The Guardian - UK

Treatment that can double bladder cancer survival rates available to 1,000 patients in England

People with disease that has spread have been found to live twice as long when given treatment hailed as ‘hopeful’

The Guardian - UK

Abortion drug could help reduce risk of breast cancer, group of medics says

Stigma around mifepristone is stopping studies, experts in reproductive health claim in Lancet opinion piece

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients

On Tuesday, Merck Co. Inc. (NYSE:MRK) released topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy.

Benzinga

IO Biotech's Combo Therapy For Skin Cancer Falls Just Short, Eyes FDA Talks Later This Year

IO Biotech (NASDAQ:IOBT) on Monday released topline results from the pivotal Phase 3 trial of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio (imsapepimut and etimupepimut, adjuvanted).

The National (Scotland)

Three new cancer drugs approved for use for NHS Scotland

Three new treatments for cancer have been approved for use by the NHS in Scotland ...

The Independent UK

The new take-at-home drug that ‘could boost effectiveness of chemotherapy’

New medicine will spare some patients from more aggressive treatments

The Independent UK

‘Game-changing’ cancer vaccine trial to begin on NHS

The jab uses mRNA technology to train the immune system to fight cancerous cells

Evening Standard

Patients to be fast-tracked on to new head and neck cancer vaccine trial

The jab uses mRNA technology to train the immune system to fight cancer.

Benzinga

Celcuity Stock Skyrockets On Breakthrough Trial Data For Heavily Pretreated Breast Cancer

Celcuity Inc. (NASDAQ:CELC) stock surged on Monday after the company reported topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial, which evaluated gedatolisib plus fulvestrant with and without palbociclib versus fulvestrant.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.